John Connolly speaks on an Endpoints News panel at the 2018 BIIS PharmCube/Endpoints conference in Shanghai (File photo)
July 24, 2020 06:27 AM EDT
People
Peer Review

Turn­ing can­cer in­to a cur­able dis­ease: Im­munother­a­py ex­pert John Con­nol­ly picks up the reins as the new CSO of Sean Park­er’s can­cer in­sti­tute

John Carroll

Editor & Founder

John Con­nol­ly synced with the folks at the Park­er In­sti­tute for Can­cer Im­munother­a­py ear­ly on.

As the sci­ence chief at Sin­ga­pore-based Tes­sa Ther­a­peu­tics, he …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times